CLINICAL_TRIALS
trial_result
· 2018-10-16
Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma [Phase 2]
Summary
Phase 2 clinical trial evaluating erlotinib hydrochloride for malignant peritoneal mesothelioma has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Chicago | Conditions: Malignant Peritoneal Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2018-10-16